Physician profile
David E Bryan
NPI 1578671418
$45,029.58
in general payments reported to CMS, 2019-2025
56 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,303 · 2020: $2,606 · 2021: $1,405 · 2022: $4,400 · 2023: $2,309 · 2024: $6,809 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Honoraria: $12K · Food and Beverage: $4,692 · Travel and Lodging: $954 · Education: $75.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,345.00 |
| Honoraria | $12,250.00 |
| Food and Beverage | $4,691.50 |
| Travel and Lodging | $954.16 |
| Education | $75.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $23,559.26 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,732.24 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $2,589.14 | 2019-2025 | Adstiladrin |
| Medtronic USA, INC. | $1,896.58 | 2019-2020 | |
| Boston Scientific Corporation | $1,063.26 | 2019-2025 | General - Kidney Stone Disease, Spaceoar Vue System - 10ml, Ams 700 |
| Dendreon Pharmaceuticals LLC | $433.78 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $418.95 | 2019-2024 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $401.77 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $394.19 | 2019-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $351.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $350.81 | 2021-2025 | Lynparza, Keytruda, Welireg |
| Neotract INC. | $347.30 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $343.44 | 2021-2025 | Prolaris |
| Urogen Pharma, INC. | $342.74 | 2022-2025 | Jelmyto |
| Antares Pharma, INC. | $248.13 | 2019-2023 | Xyosted, Tlando, Nocdurna |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.